Zagazig University, Faculty of Medicine, Internal Medicine Department, Zagazig, Egypt.
Zagazig University, Faculty of Medicine, Clinical Pathology Department, Zagazig, Egypt.
J Bras Nefrol. 2023 Oct-Dec;45(4):417-423. doi: 10.1590/2175-8239-JBN-2022-0184en.
The immune response to different Coronavirus Disease 2019 (COVID-19) vaccines is under-investigated in end-stage kidney disease (ESKD) patients, especially in the Middle East and North Africa. We carried out this research to estimate the effectiveness of COVID-19 immunization in ESKD patients on regular hemodialysis (HD).
In this prospective observational study, we enrolled 60 ESKD patients on regular HD who had completed COVID-19 vaccination and 30 vaccinated healthy participants. Serum levels of severe acute respiratory syndrome coronavirus 2 immunoglobulin G (SARS-COV2 IgG) were quantified 1 month after completing the vaccination schedule, and all participants were followed up from October 2021 to March 2022. The vaccines used in the study were from Pfizer-BioNTech, AstraZeneca, and Sinopharm.
The median level of SARS-COV2 IgG was lower in HD patients than in healthy participants (p < 0.001). Regarding the type of COVID-19 vaccination, there was no statistical difference in SARS-COV2 IgG levels among HD patients. During the observation period, none of the HD patients had COVID-19.
COVID-19 vaccination appeared to be protective in HD patients for 6 months and the side effects of vaccines were tolerable.
在终末期肾病（ESKD）患者中，包括中东和北非地区在内，针对不同的 2019 年冠状病毒病（COVID-19）疫苗的免疫反应研究不足。我们进行这项研究是为了评估 COVID-19 疫苗在接受常规血液透析（HD）的 ESKD 患者中的有效性。
在这项前瞻性观察性研究中，我们招募了 60 名已完成 COVID-19 疫苗接种的正在接受常规 HD 治疗的 ESKD 患者和 30 名接种疫苗的健康参与者。在完成疫苗接种计划后 1 个月，定量检测血清中严重急性呼吸综合征冠状病毒 2 免疫球蛋白 G（SARS-COV2 IgG）的水平，所有参与者均在 2021 年 10 月至 2022 年 3 月期间接受随访。研究中使用的疫苗来自辉瑞-生物技术公司、阿斯利康和中国国药。
HD 患者的 SARS-COV2 IgG 中位数水平低于健康参与者（p<0.001）。关于 COVID-19 疫苗类型，HD 患者之间 SARS-COV2 IgG 水平无统计学差异。在观察期间，没有 HD 患者感染 COVID-19。
COVID-19 疫苗接种似乎在 6 个月内对 HD 患者具有保护作用，且疫苗的副作用可耐受。
